tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pliant Therapeutics (PLRXResearch Report) and Nurix Therapeutics (NRIXResearch Report) with bullish sentiments.

Pliant Therapeutics (PLRX)

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Pliant Therapeutics, with a price target of $40.00. The company’s shares closed last Monday at $19.06.

According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -17.8% and a 30.3% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Lexicon Pharmaceuticals.

Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.25, implying a 151.4% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $36.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Nurix Therapeutics (NRIX)

In a report released today, Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics, with a price target of $32.00. The company’s shares closed last Monday at $17.49.

According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.0% and a 34.7% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $38.00, implying an 118.8% upside from current levels. In a report issued on July 7, RBC Capital also maintained a Buy rating on the stock with a $39.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PLRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed